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are expressed in plasmids to be used as DNA vaccine vectors. [7] The strategy includes identifying immunogenic proteins, isolating the encoding genes, cloning them into plasmid expression vectors capable of expressing the cloned genes when injected/delivered into animals intramuscularly. [8] Once into animal muscle cells, the recombinant plasmids transcribe the bacterial DNA sequence into the corresponding mRNA, followed by the expression of recombinant proteins, which sensitize the immune system of the host for induction of antigen-specific cellular and humoral immune responses capable of providing protection against the pathogen. [9] In previous studies, the major antigenic proteins encoded by genes present in M. tuberculosis-specific region of difference (RD) 1 and RD9 genomic sequences, i.e. PE35, PPE68, EsxA, EsxB, and EsxV were identified using cell-mediated immunity assays. [10] [11] [12] [13] [14] [15] [16] The DNA vaccine constructs based on these antigens were efficient inducers of antigen-specific cellular immune responses in mice. [17] Although, the role of cell-mediated immunity (CMI) in protection against M. tuberculosis infection in experimental animals and humans is well established [18] [19] [20] [21] evidence about the role of humoral immunity in the protection against and control of M. tuberculosis infection is emerging. [22] [23] [24] Therefore, in this study, we evaluated the DNA vaccine constructs of RD1 and RD9 genes for the induction of antigen-specific antibody responses in mice.
methods

Bacteria and vectors
We used pGEM-T Easy (Promega corporation, Madison, WI, USA) in strain DH5αF' (Gibco-BRL, Paisley, UK); pUMVC6 and pUMVC7 (Aldeveron, USA) in strain BL21 (Novagen, Madison, WI, USA). [25, 26] We grew Escherichia coli in standard liquid or solid media with proper antibiotics as shown previously. [25, 26] We carried out DNA manipulations, restriction digestions, and bacterial transformations according to standard procedures. [27, 28] 
Purification of recombinant proteins
We amplified the genes of M. tuberculosis RD1 (PE35, PPE68, EsxA, and EsxB) and RD9 (EsxV) using genomic DNA of M. tuberculosis H 37 Rv and gene-specific primers by polymerase chain reaction (PCR) according to standard procedures. [25] Then, we cloned the amplified DNA into pGEM-T Easy (Promega Corp., Madison WI., USA) and after that subcloned them into pGES-TH-1 plasmid as described previously [26, 27] for the expression in E. coli. Then using thrombin protease treatment, affinity chromatography glutathione-S-transferase (GST) columns, and Ni-NTA resin we purified recombinant proteins that has been expressed as fusion proteins with GST, free of the fusion partner, to near homogeneity from E. coli cells as described previously. [28, 29] 
Synthetic peptides
Overlapping synthetic peptides (25-mers overlapping neighboring peptides by 10 amino acids) covering the sequence of PE35, PPE68, EsxA, EsxB, and EsxV proteins were designed and synthesized, as described previously. [11] [12] [13] Basically, we prepared the stock concentrations (5 mg/ml) of the peptides in normal saline (0.9%) by strong pipetting and mixing, then we diluted the stock in phosphate buffered saline (PBS, pH 7.0) to prepare the working concentrations, as described previously. [11] [12] [13] 
Preparation of recombinant DNA vaccine vectors of pUMVC6 and pUMVC7
Vectors pUMVC6 and pUMVC7 (eukaryotic expression vectors) were used for cloning of PE35, PPE68, EsxA, EsxB, and EsxV genes to make DNA vaccine constructs, as described previously. [17] In brief, we amplified the DNA segments corresponding to PE35, PPE68, EsxA, EsxB, and EsxV by PCR using genomic DNA isolated from M. tuberculosis according to standard procedures. [17] Then, first we cloned DNA corresponding to each gene into pGEM-T Easy vector, and their identity was confirmed by restriction digestion with EcoR I, as described previously. [17] Then, we did single digestion of recombinant plasmids pGEM-T/PE35, pGEM-T/PPE68, pGEM-T/EsxA, pGEM-T/EsxB, and pGEM-T/EsxV with BamH I (for subcloning into pUMVC6) and double digestion with BamH I and Xba I (for subcloning into pUMVC7) to release the DNA fragment corresponding to PE35, PPE68, EsxA, EsxB, and EsxV genes with BamH I/BamH I and BamH I/Xba I cohesive termini. [17] After that, we subcloned all the genes into plasmid vectors pUMVC6 and pUMVC7 that been predigested with BamH I/BamH I and BamH I/Xba I, respectively. The recombinant plasmids were propagated in E. coli cells, as described previously. [17] According to the manufacturer's instructions, we used the Qiagen Endofree Mega kits (Qiagen, Valencia, CA, USA) to purify the recombinant and parent pUMVC6 and pUMVC7 plasmids in large quantities.
Immunization of mice with DNA vaccine constructs
We immunized groups of 6-8 week old female BALB/c mice (5 mice in each group) intramuscularly with three doses of 100 µg of plasmid DNA in 100 µl saline 3 weeks apart. The plasmids included pUMVC6, pUMVC6/PE35, pUMVC6/PPE68, pUMVC6/EsxA, pUMVC6/EsxB, pUMVC6/EsxV, pUMVC7, pUMVC7/PE35, pUMVC7/PPE68, pUMVC7/EsxA, pUMVC7/EsxB, and pUMVC7/EsxV. The mice were euthanized after 3 weeks of the last immunization, to collect blood and isolate sera to detect antigen-specific antibodies using enzyme-linked immunosorbent assays (ELISA).
Enzyme-linked immunosorbent assays to detect antibodies in mouse sera
We performed ELISA to detect antigen-specific antibodies in mouse sera were according to the standard procedures. [29] In brief, the pure recombinant proteins, peptide pools of each protein, and individual peptides of PE35, PPE68, EsxA, EsxB, and EsxV were dissolved in phosphate buffered saline (pH = 7.0) at 10 µg/ml and 100 µl of each was used to coat the wells of 96 well PolySorb plates (Nunc, USA) overnight at 37°C. The wells were blocked with 100 µl of blocking buffer (0.17 M boric acid, 0.12 M NaCl, 0.05% Tween-20, 1 mM ethylenediaminetetraacetic acid and 0.25% bovine serum albumin, pH = 8.0) for 1 h at 37°C. After three times washing with distilled water, 50 µl of diluted sera (diluted to 1:100 in blocking buffer) were added and the plates were incubated for 1 h at 37°C. The wells were washed three times with distilled water and incubated further with 50 µl of anti-mouse secondary antibody (IgG, IgM, IgA, and Sigma) conjugated to alkaline phosphatase (1:1000) for 1 h at 37°C. The wells were washed three times with distilled water, 50 µl of the substrate (p-nitrophenyl phosphate) (Sigma) was added to each well and the plates were incubated for 1 h at 37°C. We used 25 µl of 3 M NaOH to stop the reaction and we measured the optical density (OD) at 405 nm using ELISA reader. [29] We used wells that not been coated with antigens but coated with primary and secondary antibodies as a negative controls. We expressed the results as E/C, that been defined as: E/C = OD in antigen-coated wells with primary and secondary antibodies/OD in antigen uncoated wells with primary and secondary antibodies
We considered the results positive if he values of E/C >2. [29] Ethical approval Mice were immunized and handled according to approved Institutional Animal Care and Use Committee protocols at Kuwait University.
results
Antigen-specific antibodies in sera of mice immunized with parent and recombinant plasmids
Antigens-specific antibodies were not detected in the sera of mice immunized with parent plasmids pUMVC6 and pUMVC7 (E/C <2.0) [Figures 1a and b ]. However, antigen-specific antibodies against full-length recombinant proteins were detected in sera of all groups of mice immunized with the homologous recombinant DNA vaccine constructs of pUMVC6 and pUMVC7 (E/C >2.0) [Figures 2 and 3 for sera from mice immunized with recombinant pUMVC6 and pUMVC7, respectively]. These results confirmed the in vivo expression and immunogenicity of all the genes cloned in both vectors. However, relatively high titers of antibodies in response to four of the five proteins were detected in sera from mice immunized with recombinant pUMVC6 than recombinant pUMVC7 [ Table 1 ].
Peptides reactive with antibodies in sera of mice immunized with DNA vaccine constructs
To determine if the linear epitopes were recognized by antibodies and to identify the epitopes recognized, the mice sera were further tested with peptide mixtures and single peptides of each protein in ELISA. The peptide mixture of PPE68 yielded positive ELISA reactivity with sera from mice immunized with both vaccine constructs, i.e. pUMVC6-PPE68 and pUMVC7-PPE68 [ Figures 4 and 5b] . However, the immunoreactive peptides were variable, i.e., P24 and P19 in mice immunized with pUMVC6-PPE68 [ Figure 4b ] and The results shown are average E/C values for 5 mice. E/C is defined as: E/C=OD 405 in antigen coated wells with mouse sera and secondary antibody/OD 405 in antigen uncoated wells with mouse sera and secondary antibody. OD: Optical density 
dIscussIon
There is a need to develop new vaccines for TB as the current BCG vaccine failed to protect humen from TB. DNA vaccines are considered attractive in this regard as they elicit protective immune responses, e.g. Th1 biased CD4 + responses and strong CTL responses. [31] Previously, EsxA (ESAT-6) protein has been evaluated as a DNA vaccine in mice and the results showed that this vaccine elicits Th1-type immunity. [32] In another study, Maue et al. have shown that an ESAT-6:CFP10 DNA vaccine administered in cattle induced Th1-cell responses and in conjunction with BCG conferred protection against challenge with virulent Mycobacterium bovis. [33] Furthermore, the protection provided by PE and PPE (Rv1806-1807, Rv3812) proteins against M. tuberculosis challenge in mice was reported by Vipond et al. [34] However, recent studies have suggested that both cellular and humoral responses may be required to provide optimal and efficient protection after immunization with vaccines. [32, 24] Although, the induction of cellular responses to all the major antigens of RD1 and RD9, after immunization with the recombinant DNA vaccine constructs, have been reported previously, [17, 35, 36] the antibody responses are reported for the first time in this study.
Figure 2:
Antigen-specific antibody reactivities in sera from mice immunized with the DNA vaccine constructs pUMVC6/PE35 (a), pUMVC6/PPE68 (b), pUMVC6/EsxA (c), pUMVC6/EsxB (d) and pUMVC6/EsxV (e). Sera from five individual mice (M1 to M5) immunized with the recombinant pUMVC6 plasmids were tested for antibody reactivity with enzyme-linked immunosorbent assays using pure recombinant proteins and mixtures of synthetic peptides of PE35, PPE68, EsxA, EsxB and EsxV. Data are presented as E/C were calculated and values >2 were considered positive, as described in materials and methods In this study, recombinant DNA plasmid constructs employing two vectors (pUMCV6 and pUMCV7) were used to immunize groups of mice. Although we observed positive antigen-specific antibody (this study) and CMI responses [17] in response to all of the antigens after immunization of mice with both recombinant plasmids, but recombinant pUMCV6 induced relatively better responses than recombinant pUMCV7. Both vectors share the same promoter (CMV promoter), but they differ in the peptide that is fused with the foreign protein to be expressed as a recombinant fusion protein. The fusion peptide is human interleukin-2 (hIL −2 ) secretory protein in pUMCV6 [17] and it is the tissue plasminogen activator (tPA) signal peptide in pUMCV7. [17] The hIL2 secretory protein acted as a better adjuvant for both cellular and humoral immune responses to the fused mycobacterial proteins more effectively than the tPA signal peptide as seen by the improved responses with recombinant pUMCV6.
To determine if the linear epitopes were involved and to identify the epitopes recognized by antibodies induced by immunization with recombinant DNA constructs in mice, the sera were further tested with mixtures of overlapping synthetic peptides corresponding to each protein, followed by testing with each peptide. The results showed that antibody titers to peptide mixtures were lower as compared to full-length proteins, and peptide mixtures of only PE35 and PPE68 showed significant antibody reactivity. Furthermore, the antibody reactivity was limited to only one out of six peptides of PE35 and only two of 24 peptides of PPE68. These results suggest that most of the epitopes of RD1 and RD9 proteins recognized by antibodies present in mouse sera were conformational in nature. In another study using rabbits, immunization with purified recombinant proteins has been shown to induce antibody reactivity to multiple peptides of each protein studied in this work. [29] In the case of rabbits, the antigens were vigorously emulsified in incomplete Freund's adjuvant, which denatures and fragments the proteins into smaller peptides exposing the linear epitopes for B cell recognition and antibody secretion. Thus, these antibodies will be recognized by both full-length proteins as well as small size linear peptides. Whereas recombinant plasmids were injected intramuscularly in isotonic PBS, the muscle cells take up the plasmids and facilitate the expression of the proteins in vivo. This will help to maintain the conformational epitopes of the expressed proteins for recognition by B cells that will eventually differentiate into plasma cells to secrete antibodies, which will mostly recognize the conformational epitopes in the immunizing proteins.
conclusIon
All the RD proteins were expressed in mice immunized with both DNA vaccine constructs and induced antibody responses to the immunizing proteins. Furthermore, experiments with synthetic peptides suggest that most of the epitopes recognized by antibodies were conformational in nature. The induction of both cellular and humoral responses to the antigens delivered through DNA vaccine constructs supports their use as new Figure 4 : Antigen-specific antibody reactivities to individual peptides in sera from mice immunized with the DNA vaccine constructs pUMVC6/PE35 (a), pUMVC6/PPE68 (b), pUMVC6/EsxA (c), pUMVC6/EsxB (d) and pUMVC6/EsxV (e). Pooled sera from five mice immunized with the recombinant pUMVC6 plasmids were tested for antibody reactivity with enzyme-linked immunosorbent assays using mixtures of synthetic peptides and single peptides of PE35, PPE68, EsxA, EsxB and EsxV. Data are presented as E/C were calculated and values >2 were considered positive. The results are presented as average E/C from five mice in each group vaccines against TB. However, these constructs should be tested in appropriate animal models for protection against M. tuberculosis challenge, before they are tested in human clinical trials. 
